References
1.M. Samson, X. Puéchal, H. Devilliers C. Ribi, P. Cohen, B. Bienvenu et
al., “Mononeuritis multiplex predicts the need for immunosuppressive or
immunomodulatory drugs for EGPA, PAN and MPA patients without
poor-prognosis factors,” Autoimmunity Reviews, vol. 13, no. 9, pp.
945–953, 2014.
2.C. Comarmond, C. Pagnoux, M. Khellaf, J. Cordier, M.Hamidou, J.
Viallard et al., “Eosinophilic granulomatosis with polyangiitis
(Churg-Strauss): clinical characteristics and long-term followup of the
383 patients enrolled in the French Vasculitis Study Group cohort,”
Arthritis & Rheumatism, vol. 65, no. 1, pp. 270–281, 2013.
3.J. Wolf, V. Schmitt, F. Palm, A. J. Grau, and R. Bergner, “Peripheral
neuropathy as initial manifestation of primary systemic vasculitides,”
Journal of Neurology, vol. 260, no. 4, pp. 1061–1070, 2013.
4. Cattaneo L, Chierici E, Pavone L, Grasselli C, Manganelli P, Buzio C,
et al. Peripheral neuropathy in Wegener’s granulomatosis, Churg-Strauss
syndrome and microscopic polyangiitis. J Neurol Neurosurg Psychiatry.
2007;78:1119–23.
5. Hattori N, Ichimura M, Nagamatsu M, Li M, Yamamoto K, Kumazawa K, et
al. Clinicopathological features of Churg-Strauss syndrome-associated
neuropathy. Brain. 1999;122(Pt 3):427–39.
6. Samson M, Puéchal X, Devilliers H,
Ribi C, Cohen P, Stern M et al.
Long-term outcomes of 118 patients with eosinophilic granulomatosis with
polyangiitis (Churg-Strauss syndrome) enrolled in two prospective
trials. J 2013;43(6):60–69.